10-Q: Venus Concept Reports Q2 Loss Amid Revenue Decline, Asset Sale

Venus Concept Inc. reported a decrease in Q2 2025 revenue and gross profit, alongside a worsening Adjusted EBITDA loss, while announcing the sale of its Venus Hair Business for $20 million.

Summary

• Total revenue decreased by 5.4% to $15.7 million for the three months ended June 30, 2025, from $16.6 million in the prior year period.
• Total revenue for the six months ended June 30, 2025, decreased by 13.9% to $29.3 million from $34.1 million in the prior year period.
• Gross profit decreased by 20.4% to $9.4 million for the three months ended June 30, 2025, with gross margin falling to 60.1% from 71.5% in the prior year.
• Net loss attributable to stockholders improved to $(11.7) million for the three months ended June 30, 2025, compared to $(19.9) million in the prior year, primarily due to lower loss on debt extinguishment.
• Adjusted EBITDA loss worsened to $(8.8) million for the three months ended June 30, 2025, from $(4.1) million in the prior year.
• Cash used in operating activities for the six months ended June 30, 2025, was $(11.7) million, a significant increase from $(4.2) million in the prior year.
• The company entered into a Unit Purchase Agreement on June 5, 2025, to sell its Venus Hair Business (ARTAS and NeoGraft technologies) to Meta Healthcare Group for $20 million in cash, subject to customary adjustments and closing conditions, expected in Q3 2025.
• Multiple debt exchanges occurred, including a March 31, 2025, exchange of $28.0 million in notes for $17.0 million in new secured notes and 379,311 Series Y Preferred Stock, resulting in a $1.0 million non-cash loss.
• A June 30, 2025, exchange of $17.0 million in notes for $11.1 million in a new promissory note and 325,651 Series Y Preferred Stock resulted in a $1.9 million non-cash loss.
• The maturity dates for the MSLP Loan and EW Notes were extended from December 2025 to December 2026.
• The company completed registered direct offerings in April and June 2025, raising approximately $3.85 million in gross proceeds.
• As of June 30, 2025, cash, cash equivalents, and restricted cash totaled $4.9 million, up from $4.3 million at December 31, 2024.
• Total debt obligations decreased to $34.3 million as of June 30, 2025, from $39.7 million at December 31, 2024.
• The company had an accumulated deficit of $333.0 million as of June 30, 2025, up from $308.9 million at December 31, 2024.
• The company continues to face substantial doubt about its ability to continue as a going concern within 12 months due to recurring losses and negative cash flows.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in revenue and gross profit, a worsening Adjusted EBITDA loss, and increased cash burn from operations. The 'going concern' warning highlights severe financial distress. While debt maturity extensions and an asset sale provide some temporary relief and capital, these actions are reactive to ongoing liquidity challenges and do not fundamentally address the operational losses. Geopolitical risks and supply chain disruptions further compound the negative outlook.

Positives

• Net loss attributable to stockholders improved by $8.2 million for the three months ended June 30, 2025, and by $5.6 million for the six months ended June 30, 2025, compared to the prior year periods, primarily due to lower loss on debt extinguishment.
• The sale of the Venus Hair Business for $20 million in cash is expected to improve liquidity and is anticipated to close in Q3 2025.
• Cash, cash equivalents, and restricted cash increased to $4.9 million as of June 30, 2025, from $4.3 million at December 31, 2024.
• Total debt obligations decreased to $34.3 million as of June 30, 2025, from $39.7 million at December 31, 2024.
• The allowance for expected credit losses decreased by 18% to $3.1 million as of June 30, 2025, from $3.8 million at December 31, 2024, indicating improved credit screening practices.
• Maturity dates for the MSLP Loan and EW Notes were extended to December 2026, providing more financial flexibility.
• Research and development expenses decreased by 22.0% for the three months and 17.4% for the six months ended June 30, 2025, reflecting cost savings through consolidation of activities.

Negatives

• Total revenue decreased by 5.4% for the three months and 13.9% for the six months ended June 30, 2025, primarily due to economic uncertainty, tighter credit markets, and exiting unprofitable international markets.
• Gross profit decreased by 20.4% for the three months and 22.6% for the six months ended June 30, 2025, with gross margin declining significantly to 60.1% and 62.0% respectively.
• Adjusted EBITDA loss worsened to $(8.8) million for the three months and $(17.2) million for the six months ended June 30, 2025, indicating deteriorating operational profitability.
• Cash used in operating activities for the six months ended June 30, 2025, increased substantially to $(11.7) million from $(4.2) million in the prior year, highlighting increased cash burn.
• The company continues to incur substantial operating losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern within 12 months.
• Selling and marketing expenses increased by 9.0% for the three months and 1.8% for the six months ended June 30, 2025, and increased as a percentage of total revenues.
• General and administrative expenses increased by 8.9% for the three months and 1.4% for the six months ended June 30, 2025, primarily due to higher bad debt expense and inflationary pressures.
• Supply disruptions caused by the Israel-Iran conflict impacted production at the contract manufacturer's facility in Israel, contributing to revenue and gross profit declines.
• The company recognized non-cash losses on debt extinguishment of $1.0 million and $1.9 million in March and June 2025, respectively, related to debt exchanges.

Risks

• Recurring net operating losses and negative cash flows from operations raise substantial doubt about the company's ability to continue as a going concern within 12 months.
• The global economy, including financial and credit markets, is experiencing extreme volatility and disruptions, including increasing inflation rates, rising interest rates, foreign currency impacts, and declines in consumer confidence, which may adversely affect the business.
• There is no assurance that the evaluation of strategic alternatives will result in any transaction, nor can there be any assurance regarding any transaction's timing or ultimate outcome.
• The company's dependency on internal lease programs exposes it to the credit risk of customers, and customers' failure to make payments could negatively affect financial results.
• Operations in Israel expose the company to adverse effects from political, economic, geopolitical, and military conditions, including the Israel-Hamas and Israel-Iran conflicts, which could disrupt operations and supply chains.
• Insurance does not cover losses from events associated with the security situation in the Middle East, and government coverage may not be maintained or sufficient.
• The company may not be able to maintain its listing on The Nasdaq Capital Market if it fails to comply with listing requirements, which could lead to significant adverse consequences for shareholders.
• Changes in trade policies, such as increased tariffs on goods imported from Israel (10%), will increase cost of goods and lead to modest margin erosion, and uncertainty exists regarding tariffs from other countries.
• Supply chain disruptions, particularly from the Israel-Iran conflict impacting the contract manufacturer in Israel, are anticipated to continue throughout 2025, affecting production and ability to meet demand.
• The company may not be successful in raising additional capital or that such capital, if available, will be on terms acceptable to the company, potentially compelling a reduction in operations or asset sales.
• Compliance with financial covenants in credit facilities is at risk if macroeconomic headwinds continue, and lenders may not provide relief or alternative financing on favorable terms.
• The company relies on the expertise and retention of management, and loss of key personnel could adversely affect the business.

Future Outlook

The company expects to continue incurring substantial operating losses and net cash outflows from operating activities until revenue reaches a level to support its cost structure. Management plans to fund operations and capital expenditures with cash on hand, borrowings, and issuance of capital stock. The company anticipates some supply challenges during the balance of 2025 due to geopolitical disruption in the Middle East impacting shipping lanes and production lead times. It also faces uncertainty regarding tariffs, particularly the increased 10% tariff on goods imported from Israel, which will increase cost of goods and lead to modest margin erosion. The company expects the ratio of lease program sales to traditional sales to approximate a 30:70 split for the balance of 2025 and beyond, and inventory to remain relatively flat in the short term but increase at a lower rate than revenue growth over the longer term. The severity and duration of current global economic conditions and geopolitical conflicts on the business cannot be predicted.

Management Comments

• Management plans to fund operations and capital expenditures with cash on hand, borrowings, and issuance of capital stock until profitability is achieved.
• We expect to continue to incur substantial operating losses and net cash outflows from operating activities until we generate revenue at a level to support our cost structure.
• We cannot anticipate the extent to which the current financial market conditions and trade disruptions will continue to adversely impact our business.
• We remain committed to our strategy to prioritize cash deals over internal financing program deals in order to improve cash generation and preserve liquidity.
• We remain steadfast in ensuring that our in-house financing program accepts only qualified customers with the goal to reduce future credit losses, often at the expense of topline revenue.
• We continue to actively work with our suppliers and third-party manufacturers to mitigate supply issues and build inventory of key component parts.
• We anticipate some supply challenges during the balance of 2025, due to geopolitical disruption in the middle east impacting shipping lanes, deliveries of materials and component parts, impacting production lead times.
• We continue to mitigate inflationary pressures, where possible, through price increases and margin management.
• We continue to evaluate our direct operations, particularly those outside of North America, and have taken and will continue to take steps to exit countries which we do not believe will produce sustainable results.
• We remain fully focused on our revised credit screening practices with the goal of reducing bad debt expenses.
• We do not hedge our entire foreign exchange exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk.

Industry Context

The medical aesthetic and hair restoration technology industry is subject to global economic conditions, including inflation, interest rate fluctuations, and geopolitical events. Venus Concept's performance reflects these broader trends, with tightening credit markets and economic uncertainty impacting customer capital equipment purchases. The company's strategy to shift towards traditional cash sales and exit underperforming international markets aligns with efforts to adapt to a challenging macroeconomic environment. The sale of the Venus Hair Business indicates a potential focus on core aesthetic technologies or a move to streamline operations and improve liquidity in a competitive market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks. However, the reported revenue decline and worsening Adjusted EBITDA loss suggest underperformance relative to a healthy growth-oriented industry, especially given the ongoing need for capital raises and the 'going concern' warning.
• The decrease in gross margin from 71.5% to 60.1% (Q2 2024 vs Q2 2025) indicates significant pressure on profitability, potentially below industry averages for medical device companies which often maintain higher margins due to specialized technology and R&D costs.
• The company's reliance on internal lease programs (32% of system revenues YTD Q2 2025) and the associated credit risk, along with an increase in bad debt expense, could be higher than industry best practices for capital equipment financing, especially in a tightening credit market.
• The ongoing need for bridge financing and registered direct offerings, coupled with debt exchanges, suggests a more challenging capital structure and liquidity position compared to well-capitalized industry peers.

Corporate Governance

Legal Proceedings

• As of June 30, 2025, the company was not a party to any material active or pending legal proceedings.

Related Party Transactions

• There were no related party transactions for the three and six months ended June 30, 2025 and 2024, respectively.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing capital raises and debt-to-equity conversions. The 'going concern' warning and potential Nasdaq delisting pose substantial risks to investment value. The asset sale provides some liquidity but reduces the company's operational scope.
• **Employees:** Operations in Israel are exposed to geopolitical risks, potentially impacting employee safety and business continuity. Restructuring activities and exiting unprofitable markets may lead to job reductions.
• **Customers:** Tighter credit markets and higher interest rates may impact their ability to secure financing for capital equipment, affecting sales. The Venus Prime program aims to provide flexible financing but focuses on qualified customers, potentially limiting access for some.
• **Suppliers:** Supply chain disruptions due to geopolitical conflicts and inflationary pressures could affect relationships and lead to delays or increased costs.
• **Creditors:** Debt maturity extensions and debt-to-equity exchanges indicate ongoing efforts to manage debt, but the 'going concern' warning suggests elevated risk for lenders.

Next Steps

• Close the sale of the Venus Hair Business to Meta Healthcare Group in the third quarter of 2025.
• Continue to evaluate profitability and growth prospects in international markets and take steps to exit countries that do not produce sustainable results.
• Continue to focus on traditional sales and internal financing customers with stronger credit profiles to reduce exposure to credit losses.
• Actively work with suppliers and third-party manufacturers to mitigate supply issues and build inventory of key component parts.
• Monitor political and military developments in the Middle East and examine consequences for operations and assets.
• Continue to invest in research, clinical studies, and development activities, particularly for new product initiatives and enhancing current technologies.
• Manage expenses to achieve and sustain profitability, including controlling sales and marketing, general and administrative, and research and development costs.
• Seek additional equity or debt financing if profitable operations are not achieved to fund future operations and capital expenditures.

Key Dates

Recommendation

The company faces severe financial challenges, evidenced by recurring net operating losses, negative cash flows from operations, and a 'going concern' warning. Revenue and gross profit are declining, and Adjusted EBITDA loss is worsening, indicating deteriorating operational performance. While the sale of the Venus Hair Business and recent capital raises provide temporary liquidity, they are reactive measures that do not address the fundamental issues of profitability and cash burn. The company's heavy reliance on debt and equity financing, coupled with geopolitical risks, supply chain disruptions, and ongoing Nasdaq listing compliance issues, creates a highly uncertain and risky investment environment. The significant accumulated deficit and the need for continuous capital infusions suggest a high probability of further dilution and potential loss of capital for investors.

Keywords

Medical Technology, Aesthetic Devices, Hair Restoration, SEC Filing, 10-Q, Financial Results, Revenue Decline, Net Loss, Adjusted EBITDA, Going Concern, Strategic Alternatives, Asset Sale, Debt Restructuring, Capital Raise, Nasdaq Listing, Geopolitical Risk, Supply Chain, Venus Concept